<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DARAPRIM- pyrimethamineÂ tabletÂ </strong><br>Turing Pharmaceuticals LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First">DARAPRIM (pyrimethamine) is an antiparasitic compound available in tablet form for oral administration. Each scored tablet contains 25 mg pyrimethamine and the inactive ingredients corn and potato starch, lactose, and magnesium stearate.
</p>
<p>Pyrimethamine, known chemically as 5-(4-chlorophenyl)6-ethyl-2,4-pyrimidinediamine, has the following structural formula:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5368616d-6520-6f6e-2053-686b72656c69&amp;name=dar06-0000-01.jpg">
</div>
<p>C<span class="Sub">12</span>H<span class="Sub">13</span>CIN<span class="Sub">4</span></p>
<p>Mol. Wt. 248.71
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Pyrimethamine is well absorbed with peak levels occurring between 2 to 6 hours following administration. It is eliminated slowly and has a plasma half-life of approximately 96 hours. Pyrimethamine is 87% bound to human plasma proteins.
</p>
<div class="Section" data-sectionCode="49489-8">
<a name="s3"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold">Microbiology:</span> Pyrimethamine is a folic acid antagonist and the rationale for its therapeutic action is based on the differential requirement between host and parasite for nucleic acid precursors involved in growth. This activity is highly selective against plasmodia and <span class="Italics">Toxoplasma gondii</span>.
</p>
<p>Pyrimethamine possesses blood schizonticidal and some tissue schizonticidal activity against <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> parasites of humans. However, the 4-amino-quinoline compounds are more effective against the erythrocytic schizonts. It does not destroy gametocytes, but arrests sporogony in the mosquito.
</p>
<p>The action of pyrimethamine against <span class="Italics">Toxoplasma gondii</span> is greatly enhanced when used in conjunction with sulfonamides. This was demonstrated by Eyles and Coleman<span class="Sup">1</span> in the treatment of experimental <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> in the mouse. Jacobs et al<span class="Sup">2</span> demonstrated that combination of the 2 drugs effectively prevented the development of severe <span class="product-label-link" type="condition" conceptid="4028363" conceptname="Uveitis">uveitis</span> in most rabbits following the inoculation of the anterior chamber of the eye with toxoplasma.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5"></a><a name="section-3.1"></a><p></p>
<p class="First"><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">Toxoplasmosis</span>:</span> DARAPRIM is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> when used conjointly with a sulfonamide, since synergism exists with this combination.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6"></a><a name="section-3.2"></a><p></p>
<p class="First"><span class="Bold">Treatment of Acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</span> DARAPRIM is also indicated for the treatment of acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. It should not be used alone to treat acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Fast-acting schizonticides such as chloroquine or quinine are indicated and preferable for the treatment of acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. However, conjoint use of DARAPRIM with a sulfonamide (e.g., sulfadoxine) will initiate transmission control and suppression of susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of plasmodia.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-3.3"></a><p></p>
<p class="First"><span class="Bold">Chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</span> DARAPRIM is indicated for the chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> due to susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of plasmodia. However, resistance to pyrimethamine is prevalent worldwide. It is not suitable as a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> agent for travelers to most areas.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s8"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First">Use of DARAPRIM is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pyrimethamine or to any component of the formulation. Use of the drug is also contraindicated in patients with documented <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> due to <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s9"></a><a name="section-5"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">The dosage of pyrimethamine required for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> is 10 to 20 times the recommended antimalaria dosage and approaches the toxic level. If signs of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span> develop (see <a href="#s21">ADVERSE REACTIONS</a>), reduce the dosage or discontinue the drug according to the response of the patient. Folinic acid (leucovorin) should be administered in a dosage of 5 to 15 mg daily (orally, IV, or IM) until normal hematopoiesis is restored.
</p>
<p>Data in 2 humans indicate that pyrimethamine may be carcinogenic; a 51-year-old female who developed <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic granulocytic leukemia</span> after taking pyrimethamine for 2 years for <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span><span class="Sup">3</span> and a 56-year-old patient who developed reticulum cell <span class="product-label-link" type="condition" conceptid="4084784" conceptname="Sarcoma">sarcoma</span> after 14 months of pyrimethamine for <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>.<span class="Sup">4</span></p>
<p>Pyrimethamine has been reported to produce a significant increase in the number of lung tumors in mice when given intraperitoneally at doses of 25 mg/kg.<span class="Sup">5</span></p>
<p>DARAPRIM should be kept out of the reach of infants and children as they are extremely susceptible to adverse effects from an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> in pediatric patients have been reported after accidental ingestion.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s10"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s11"></a><a name="section-6.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> The recommended dosage for chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> should not be exceeded. A small â€œstartingâ€? dose for <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> is recommended in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span> to avoid the potential nervous system toxicity of pyrimethamine. DARAPRIM should be used with caution in patients with impaired renal or hepatic function or in patients with possible <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span>, such as individuals with <span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">malabsorption syndrome</span>, <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, or pregnancy, and those receiving therapy, such as phenytoin, affecting folate levels (see <a href="#s17">Pregnancy</a> subsection).
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s12"></a><a name="section-6.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Patients should be warned that at the first appearance of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> they should stop use of DARAPRIM and seek medical attention immediately. Patients should also be warned that the appearance of <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pallor</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, or <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span> may be early indications of serious disorders which require treatment with DARAPRIM to be stopped and medical treatment to be sought.
</p>
<p>Women of childbearing potential who are taking DARAPRIM should be warned against becoming pregnant. Patients should be warned to keep DARAPRIM out of the reach of children. Patients should be advised not to exceed recommended doses. Patients should be warned that if <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occur, they may be minimized by taking the drug with meals.
</p>
<p>Concurrent administration of folinic acid is strongly recommended when used for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> in all patients.
</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s13"></a><a name="section-6.3"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests:</span> In patients receiving high dosage, as for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>, semiweekly blood counts, including platelet counts, should be performed.
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s14"></a><a name="section-6.4"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions:</span> Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. However, the concomitant use of other antifolic drugs or agents associated with <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> including sulfonamides or trimethoprim-sulfamethoxazole combinations, proguanil, zidovudine, or cytostatic agents (e.g., methotrexate), while the patient is receiving pyrimethamine, may increase the risk of bone marrow suppression. If signs of <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folate deficiency</span> develop, pyrimethamine should be discontinued. Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored (see <a href="#s9">WARNINGS</a>). Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s15"></a><a name="section-6.5"></a><p></p>
<p class="First"><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span> See <a href="#s9">WARNINGS</a> section for information on carcinogenesis.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-6.5.1"></a><p></p>
<p class="First"><span class="Bold Italics">Mutagenesis:</span> Pyrimethamine has been shown to be nonmutagenic in the following <span class="Italics">in vitro</span> assays: the Ames point mutation assay, the Rec assay, and the <span class="Italics">E coli</span> WP2 assay. It was positive in the L5178Y/TK +/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay in the absence of exogenous metabolic activation.<span class="Sup">6</span> Human blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> cultured <span class="Italics">in vitro</span> had structural chromosome aberrations induced by pyrimethamine.
</p>
<p><span class="Italics">In vivo,</span> chromosomes analyzed from the bone marrow of rats dosed with pyrimethamine showed an increased number of structural and numerical aberrations.
</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s17"></a><a name="section-6.6"></a><p></p>
<p class="First"><span class="Bold">Pregnancy:
</span><span class="Bold Italics">Teratogenic Effects:</span> Pregnancy Category C. Pyrimethamine has been shown to be teratogenic in rats when given in oral doses 7 times the human dose for chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> or 2.5 times the human dose for treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>. At these doses in rats, there was a significant increase in abnormalities such as <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, brachygnathia, oligodactyly, and microphthalamia. Pyrimethamine has also been shown to produce terata such as <span class="product-label-link" type="condition" conceptid="4062639" conceptname="Meningocele">meningocele</span> in hamsters and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> in miniature pigs when given in oral doses 170 and 5 times the human dose, respectively, for chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> or for treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>.
</p>
<p>There are no adequate and well-controlled studies in pregnant women. DARAPRIM should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
<p>Concurrent administration of folinic acid is strongly recommended when used for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> during pregnancy.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s18"></a><a name="section-6.7"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> Pyrimethamine is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from pyrimethamine and from concurrent use of a sulfonamide with DARAPRIM for treatment of some patients with <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see <a href="#s9">WARNINGS</a> and <a href="#s17">PRECAUTIONS: Pregnancy</a>).
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s19"></a><a name="section-6.8"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> See <a href="#s23">DOSAGE AND ADMINISTRATION</a> section.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s20"></a><a name="section-6.9"></a><p></p>
<p class="First"><span class="Bold">Geriatric Use:</span> Clinical studies of DARAPRIM did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s21"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, occasionally severe (such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>), and hyperphenylalaninemia, can occur particularly when pyrimethamine is administered concomitantly with a sulfonamide. Consult the complete prescribing information for the relevant sulfonamide for sulfonamide-associated adverse events. With doses of pyrimethamine used for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur. <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> may be minimized by giving the medication with meals; it usually disappears promptly upon reduction of dosage. Doses used in <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> may produce <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, atrophic <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, and disorders of cardiac rhythm. Hematologic effects, however, may also occur at low doses in certain individuals (see <a href="#s11">PRECAUTIONS; General</a>).
</p>
<p><span class="product-label-link" type="condition" conceptid="252942" conceptname="Asthmatic pulmonary eosinophilia">Pulmonary eosinophilia</span> has been reported rarely.
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s22"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE
</h1>
<p class="First">Following the ingestion of 300 mg or more of pyrimethamine, gastrointestinal and/or central nervous system signs may be present, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. The initial symptoms are usually gastrointestinal and may include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, severe and repeated <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, possibly including <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>. Central nervous system toxicity may be manifest by initial <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span>, generalized and prolonged <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> which may be followed by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> within a few hours. Neurological symptoms appear rapidly (30 minutes to 2 hours after drug ingestion), suggesting that in gross overdosage pyrimethamine has a direct toxic effect on the central nervous system.
</p>
<p>The fatal dose is variable, with the smallest reported fatal single dose being 375 mg. There are, however, reports of pediatricpatientswhohaverecoveredaftertaking375to625mg.
</p>
<p>There is no specific antidote to acute pyrimethamine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. In the event of overdosage, symptomatic and supportive measures should be employed. Gastric lavage is recommended and is effective if carried out very soon after drug ingestion. Parenteral diazepam may be used to control <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Folinic acid should be administered within 2 hours of drug ingestion to be most effective in counteracting the effects on the hematopoietic system (see <a href="#s9">WARNINGS</a>). Due to the long half-life of pyrimethamine, daily monitoring of peripheral blood counts is recommended for up to several weeks after the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> until normal hematologic values are restored.
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s23"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s24"></a><a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">For Treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">Toxoplasmosis</span></span>: The dosage of DARAPRIM for the treatment of <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> must be carefully adjusted so as to provide maximum therapeutic effect and a minimum of side effects. At the dosage required, there is a marked variation in the tolerance to the drug. Young patients may tolerate higher doses than older individuals. Concurrent administration of folinic acid is strongly recommended in all patients.
</p>
<p>The adult <span class="Italics">starting</span> dose is 50 to 75 mg of the drug daily, together with 1 to 4 g daily of a sulfonamide of the sulfapyrimidine type, e.g. sulfadoxine. This dosage is ordinarily continued for 1 to 3 weeks, depending on the response of the patient and tolerance to therapy. The dosage may then be reduced to about one half that previously given for each drug and continued for an additional 4 to 5 weeks.
</p>
<p>The pediatric dosage of DARAPRIM is 1 mg/kg/day divided into 2 equal daily doses; after 2 to 4 days this dose may be reduced to one half and continued for approximately 1 month. The usual pediatric sulfonamide dosage is used in conjunction with DARAPRIM.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s25"></a><a name="section-9.2"></a><p></p>
<p class="First"><span class="Bold">For Treatment of Acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:</span> DARAPRIM is NOT recommended alone in the treatment of acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. Fast-acting schizonticides, such as chloroquine or quinine are indicated for treatment of acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span>. However, DARAPRIM at a dosage of 25 mg daily for 2 days with a sulfonamide will initiate transmission control and suppression of non-<span class="product-label-link" type="condition" conceptid="438343" conceptname="Falciparum malaria">falciparum malaria</span>. DARAPRIM is only recommended for patients infected in areas where susceptible plasmodia exist. Should circumstances arise wherein DARAPRIM must be used alone in semi-immune persons, the adult dosage for acute <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">malaria</span> is 50 mg for 2 days; children 4 through 10 years old may be given 25 mg daily for 2 days. In any event, clinical cure should be followed by the once-weekly regimen described below for chemoprophylaxis. Regimens which include suppression should be extended through any characteristic periods of early recrudescence and late relapse i.e., for at least 10 weeks in each case.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s26"></a><a name="section-9.3"></a><p></p>
<h2>For Chemoprophylaxis of <span class="product-label-link" type="condition" conceptid="438067" conceptname="Malaria">Malaria</span>:
</h2>
<p class="First">Adults and pediatric patients over 10 years â€“ 25 mg (1 tablet) once weekly
</p>
<p>Children 4 through 10 years â€“ 12.5 mg (1/2 tablet) once weekly
</p>
<p>Infants and children under 4 years â€“ 6.25 mg (1/4 tablet) once weekly.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s27"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED:
</h1>
<p class="First">White, scored tablets containing 25 mg pyrimethamine, imprinted with â€œDARAPRIMâ€? and "A3A" in bottles of 100 (NDC 69413-330-10).
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s28"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold">Store at 15Â° to 25Â°C (59Â° to 77Â°F) in a dry place and protect from light.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s29"></a><a name="section-11"></a><p></p>
<h1>REFERENCES
</h1>
<ol class="Arabic">
<li>Eyles DE, Coleman N. Synergistic effect of sulfadiazine and Daraprim against experimental <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span> in the mouse. <span class="Italics">Antibiot Chemother</span> 1953;3:483-490.
</li>
<li>Jacobs L, Melton ML, Kaufman HE. Treatment of experimental ocular <span class="product-label-link" type="condition" conceptid="440653" conceptname="Toxoplasmosis">toxoplasmosis</span>. <span class="Italics">Arch Ophthalmol</span>. 1964;71:111-118.
</li>
<li>Jim RTS, Elizaga FV. Development of <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic granulocytic leukemia</span> in a patient treated with pyrimethamine. <span class="Italics">Hawaii Med J</span>. 1977;36:173-176.
</li>
<li>Sadoff L. Antimalarial drugs and Burkitt's <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>. <span class="Italics">Lancet.</span> 1973;2:1262-1263.
</li>
<li>Bahna L. Pyrimethamine. <span class="Italics">LARC Monogr Eval Carcinog Risk Chem</span>. 1977;13:233-242.
</li>
<li>Clive D, Johnson KO, Spector JKS, et al. Validation and characterization of the L5178Y/TK +/- mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> mutagen assay system. <span class="Italics">Mut Res</span>. 1979;59:61-108.
</li>
</ol>
<p class="First">Distributed by:<br>Turing Pharmaceuticals LLC<br>New York, New York 10036
</p>
<p>004967-PI-001Â  Â  Â  Â Rev. 09/2015<br>015362
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s30"></a><a name="section-12"></a><p></p>
<h1>Principal Display Panel - Bottle Label
</h1>
<p class="First">TURING <br>PHARMACEUTICALS
</p>
<p>NDC 69413-330-10
</p>
<p><span class="Bold">DARAPRIM</span><span class="Bold"><span class="Sup">Â®
</span></span><span class="Bold"><br>(pyrimethamine) 25mg tablets</span></p>
<p>Each scored tablet contains <br><span class="Bold">25 mg</span></p>
<p><span class="Bold">Rx only</span>  100 Tablets
</p>
<p><span class="Bold">015361</span></p>
<p><span class="Bold">LOT</span></p>
<p><span class="Bold">EXP</span></p>
<div class="Figure">
<a name="f02"></a><img alt="Principal Display Panel - Bottle Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5368616d-6520-6f6e-2053-686b72656c69&amp;name=dar06-0000-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DARAPRIMÂ 		
					</strong><br><span class="contentTableReg">pyrimethamine tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:69413-330</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PYRIMETHAMINE</strong> (PYRIMETHAMINE) </td>
<td class="formItem">PYRIMETHAMINE</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, POTATO</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white (white) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">DARAPRIM;A3A
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:69413-330-10</td>
<td class="formItem">100  in 1 BOTTLE, GLASS; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA008578</td>
<td class="formItem">01/23/1953</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Turing Pharmaceuticals LLC
							(079604693)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fukuzyu Pharmaceutical Co., Ltd.</td>
<td class="formItem"></td>
<td class="formItem">692442510</td>
<td class="formItem">API MANUFACTURE(69413-330)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Patheon Manufacturing Services LLC</td>
<td class="formItem"></td>
<td class="formItem">079415560</td>
<td class="formItem">ANALYSIS(69413-330), MANUFACTURE(69413-330), PACK(69413-330)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>b38fb0c6-6702-4382-87cc-2676ff28b328</div>
<div>Set id: 5368616d-6520-6f6e-2053-686b72656c69</div>
<div>Version: 2</div>
<div>Effective Time: 20150928</div>
</div>
</div>Â <div class="DistributorName">Turing Pharmaceuticals LLC</div></p>
</body></html>
